RBC Capital Starts Neos Therapeutics (NEOS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts NEOS Hot Sheet
Price: $1.15 --0%
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
RBC Capital initiated coverage on Neos Therapeutics (NASDAQ: NEOS) with an Outperform rating and a price target of $35.00.
For an analyst ratings summary and ratings history on Neos Therapeutics click here. For more ratings news on Neos Therapeutics click here.
Shares of Neos Therapeutics closed at $20.63 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Starts Yamazaki Baking Co Ltd (2212:JP) at Buy
- Craig-Hallum Starts OraSure Technologies (OSUR) at Buy, PT $7
- Cantor Fitzgerald Starts Immunic Inc. (IMUX) at Overweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
